1. BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFE. (17th June 2021) Authors: Ionova, T.; Andrievskikh, M.; Amdiev, A.; Baryakh, E.; Chang, V.; Endakova, A.; Fadeeva, N.; Husainova, G.; Ivanov, V.; Kaplanov, K.; Kaverina, O.; Kiseleva, M.; Klitochenko, T.; Kurakin, V.; Larionova, O.; Lazareva, D.; Lepik, K.; Lysenko, I.; Melnichenko, V.; Mikhailova, N. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD): RESULTS OF A REAL-WORLD EVIDENCE STUDY. (23rd June 2022) Authors: Ionova, T.; Vinogradova, O.; Kochkareva, Y.; Ado, E.; Kaplanov, K.; Shirokova, M.; Shelekhova, T.; Levanov, A.; Kopylova, A.; Li, O.; Mitina, T.; Rukavitsyn, O.; Simashova, P.; Anchukova, L.; Babich, E.; Dasheeva, D.; Demchenkova, M.; Dubov, S.; Esenina, T.; Ivanova, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1892 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗